|
市場調查報告書
美國給藥系統市場
Drug Delivery Systems
|
本報告已在2012年01月27日停止出版。
更改為出版
Drug Delivery Products
出版日期 : 2011年01月
商品編碼: 229886
美國給藥系統（DDS）的需求預計未來將以每年10%以上的速度成長，到2012年達到1320億美元的規模。
本報告書內容包括：美國給藥系統市場過去的需求資料（1997年、2002年、2007年）、2012年及2017年產品別、應用別預測、市場環境、市場佔有率及主要企業介紹等資訊。內容綱要摘記如下：
介紹
第1章 實施概要
第2章 市場環境
- 概要
- 總體經濟環境
- 人口型態
- 醫療動向
- 藥品市場預測
第3章 給藥物質
- 概要
- 消毒水及精製水
- 合成聚合物
- 纖維素衍生物
- 礦物質
- 其他給藥物質
第4章 給藥系統ソ概要
- 概要
- 給藥系統的種類
- 過去的需求類型
- 規範限制
- 研發
- 美國市場的交易
- 國際市場
第5章 口服給藥系統
- 概要
- 放出制御製劑
- 可嚼錠
- 口溶錠
- 奈米粒子製劑
- 經黏膜製劑
第6章 非口服給藥系統
第7章 吸入・經皮・植入型給藥系統
- 概要
- 吸入型給藥系統
- 經皮給藥系統
- 植入型給藥系統
第8章 應用
- 概要
- 中樞神經系統用藥
- 呼吸器官用藥
- 荷爾蒙
- 胃腸藥
- 心血管藥
- 抗傳染症藥
- 營養劑
- 生物製劑
- 泌尿系統用藥
- 其他
第9章 産業構造
- 概要
- 市場佔有率
- 競爭策略
- M&A
- 授權及相關合約
- 行銷及通路
- 製造
企業介紹
Abstract
Demand to grow more than 10% annually through 2012
US demand for drug delivery systems is projected to expand more than ten
percent annually to $132 billion in 2012. Growth opportunities for drug
delivery systems extend into all therapeutic classes of pharmaceuticals and
encompass a wide range of compounds and formulations. Central nervous system,
respiratory and hormone and related agents will remain the top three
applications based on the special formulating needs of medicines for
conditions such as arthritis, multiple sclerosis, asthma, allergies and
cancer. However, favorable growth opportunities will emerge for drug delivery
systems in most other therapeutic classes due to safety and efficacy
shortcomings in many conventional medicines.
Parenteral types to exhibit best growth opportunities
Oral drug delivery systems will remain the largest method used for drug
delivery. Orally disintegrating tablets and transmucosal drugs will generate
strong growth opportunities in the delivery of pain control and other critical
care medication. Ease of administration advantages will promote the widening
use of chewable tablet dosages for nutritional, respiratory and central
nervous system agents, especially pediatric preparations. Better solubility
and pharmacokinetic actions will lead to rapid growth both in the number and
sales of oral nanoparticle drugs.
Among pharmaceutical dosage formulations, parenteral preparations will provide
the strongest growth opportunities for drug delivery systems. Precise
targeting advantages in the treatment of cancer and other debilitating
diseases will broaden demand for therapeutic monoclonal antibodies. Extended
circulation and reduced toxicity benefits will expand the range of indications
served by polymer- and liposome-encapsulated drugs, especially in the areas of
cancer, neurological and anti-infective therapies. Ease of administration and
infection prevention advantages will boost the market for parenteral drugs and
solutions sold in prefilled syringes and premixed IV systems.
An increasing incidence of chronic respiratory conditions, coupled with the
need for safer and more effective therapies, will boost growth prospects for
inhalation drug delivery systems. Based on widespread use in asthma therapy,
dry powder inhaler formulations will continue to record the largest share of
sales. However, metered dose drugs will see slightly faster gains in demand
due to ongoing improvements in particle size and propellent safety. Lastly,
transdermal patches will continue to broaden pharmaceutical applications as
advances in administration modalities and design lead to new uses in pain
control and cardiovascular medication.
Study coverage
This new Freedonia industry study, Drug Delivery Systems, presents historical
demand data (1997, 2002, 2007) plus forecasts for 2012 and 2017 by type and
application. The study also considers US market environment factors, evaluates
company market share and profiles 43 industry competitors.
Table of Contents
INTRODUCTION
I. EXECUTIVE SUMMARY
II. MARKET ENVIRONMENT
- General
- Macroeconomic Trends
- Demographic Patterns
- Health Care Trends
- Health Insurance
- Medical Conditions
- Acute Conditions
- Chronic Conditions
- National Health Expenditures
- Medical Providers
- Outpatient Clinics
- Skilled Nursing Homes
- Acute Care Hospitals
- Physicians
- Patient Activity
- Acute Care Hospital Admissions
- Surgical Procedures
- Outpatient Visits
- Pharmaceutical Market Overview
- Regulation
- Research & Development
- Demand Patterns & Forecasts
- Therapeutic Classes
- Generic Competition
- Dosage Formulations
- Regulatory Classifications
III. DRUG DELIVERY MATERIALS
- General
- Sterile & Purified Water
- Synthetic Polymers
- Polyethylene Glycol (PEG)
- Acrylic Polymers
- Carbomers
- Methacrylate Copolymers
- Polyethylene Oxide
- Polyvinyl Alcohol
- Other Synthetic Polymers
- Cellulose Derivatives
- Ethyl Cellulose
- Hydroxypropyl Methylcellulose (HPMC)
- Other Cellulose Derivatives
- Minerals
- Mineral Hydrocarbons
- Petrolatum
- Mineral Oil
- Mineral Hydrocarbon Waxes
- Other Minerals
- Attapulgite
- Calcium Carbonate
- Calcium Silicate
- Electrolytes
- Other Drug Delivery Materials
- Starch Compounds
- Cyclodextrins
- Dextrates
- Dextrin
- Maltodextrin
- Sugars & Polyols
- Sucrose
- Sorbitol
- Lactose
- Mannitol
- Natural Gums
- All Other Drug Delivery Materials
IV. DRUG DELIVERY SYSTEMS OVERVIEW
- General
- Types of Drug Delivery Systems
- Historical Demand Patterns
- Regulation
- Research & Development
- US Trade
- International Markets
V. ORAL DRUG DELIVERY SYSTEMS
- General
- Controlled-Release Formulations
- Technologies
- Coated Systems
- Diffusion Systems
- Reservoir Systems
- Chewable Tablets
- Orally Disintegrating Tablets
- Nanoparticulate Formulations
- Ethical Pharmaceuticals
- Over-the-Counter Drugs
- Transmucosal Formulations
VI. PARENTERAL DRUG DELIVERY SYSTEMS
- General
- Therapeutic Monoclonal Antibodies
- Technology
- Anti-Cancer Agents
- Other Therapeutic Monoclonal Antibodies
- Products in Development
- Prefilled Syringes
- Applications
- Injectors
- Cartridges & Insulin Pens
- Encapsulated Systems
- Polymer-Protected Systems
- PEGylated Formulations
- Other Polymer-Protected Pharmaceuticals
- Liposomes
- Developmental Activities
- Premixed IV Solutions
- Mini-Bags
- Bag/Vial Infusion Systems
- Applications
VII. INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- General
- Inhalation Drug Delivery Systems
- Dry Powder Formulations
- Devices & Technologies
- Applications
- Metered Dose Formulations
- Devices & Technologies
- Applications
- Transdermal Drug Delivery Systems
- Products & Technologies
- Developers & Suppliers
- Applications
- Implantable Drug Delivery Systems
- Drug-Eluting Stents
- Drug Inserts
- Brachytherapy
VIII. APPLICATIONS
- General
- Central Nervous System Agents
- Respiratory Agents
- Hormones & Related Agents
- Gastrointestinal Agents
- Cardiovascular Agents
- Anti-Infective Agents
- Nutritional Agents
- Biologicals
- Genito-Urinary Agents
- Other Therapies
IX. INDUSTRY STRUCTURE
- General
- Developmental Revenues
- Market Share
- Competitive Strategies
- Mergers & Acquisitions
- Licensing & Related Agreements
- Marketing & Distribution
- Manufacturing
COMPANY PROFILES
- Alkermes Incorporated
- AptarGroup Incorporated
- Aradigm Corporation
- Associated British Foods plc
- Aveva Drug Delivery Systems, see Nitto Denko
- Baxter International Incorporated
- Becton, Dickinson and Company
- Bespak, see Consort Medical
- Cardinal Health Pharmaceutical Technologies and Services, see Catalent
Pharma Solutions
- Catalent Pharma Solutions Incorporated
- Cephalon Incorporated
- CIMA LABS, see Cephalon
- Consort Medical plc
- Corium International Incorporated
- CyDex Pharmaceuticals Incorporated
- Depomed Incorporated
- Dow Corning Corporation
- DURECT Corporation
- Elan Corporation plc
- Emisphere Technologies Incorporated
- Encore Medical, see ReAble Therapeutics
- Eurand NV
- Flamel Technologies SA
- Genzyme Corporation
- Hospira Incorporated
- IOMED, see ReAble Therapeutics
- Johnson & Johnson
- Nastech Pharmaceutical Company Incorporated
- Nektar Therapeutics
- Nitto Denko Corporation
- NOF Corporation
- Penwest Pharmaceuticals Company
- ReAble Therapeutics Incorporated
- Safety Syringes Incorporated
- SPI Pharma, see Associated British Foods
- StrataGent Life Sciences, see Corium International
- 3M Company
- Valeritas LLC
- Valois SAS, see AptarGroup
- Other Companies Mentioned in Study
LIST OF TABLES
SECTION I -- EXECUTIVE SUMMARY
SECTION II -- MARKET ENVIRONMENT
- Macroeconomic Indicators
- Population by Age Group
- Acute Conditions by Type
- Chronic Conditions by Type
- National Health Expenditures by Type
- Medical Providers by Type
- Patient Activity by Type
- Pharmaceutical Demand by Therapeutic Class
- Pharmaceutical Demand by Commercial Status
- Pharmaceutical Demand by Dosage Formulation
- Pharmaceutical Demand by Regulatory Classification
SECTION III -- DRUG DELIVERY MATERIALS
- Drug Delivery Material Demand by Type
- Sterile & Purified Water Demand in Drug Delivery
- Synthetic Polymer Demand in Drug Delivery
- Cellulose Derivative Demand in Drug Delivery
- Mineral Demand in Drug Delivery
- Other Material Demand in Drug Delivery
SECTION IV -- DRUG DELIVERY SYSTEMS OVERVIEW
- Drug Delivery System Demand by Dosage Formulation
- Drug Delivery System Demand, 1997-2007
- US Trade in Drug Delivery Systems
- World Drug Delivery System Demand by Region
SECTION V -- ORAL DRUG DELIVERY SYSTEMS
- Oral Drug Delivery System Demand by Type
- Oral Controlled-Release Drug Delivery System Demand
- Coated Controlled-Release Drug Delivery System Demand
- Diffusion Controlled-Release Drug Delivery System Demand
- Reservoir Controlled-Release Drug Delivery System Demand
- Chewable Tablet Demand by Therapeutic Class
- Orally Disintegrating Tablet Demand by Therapeutic Class
- Nanoparticulate Oral Drug Delivery System Demand by Therapeutic Class
- Oral Transmucosal Drug Delivery System Demand by Therapeutic Class
SECTION VI -- PARENTERAL DRUG DELIVERY SYSTEMS
- Parenteral Drug Delivery System Demand by Type
- Therapeutic Monoclonal Antibody Demand by Therapeutic Class
- Therapeutic Monoclonal Antibodies Approved for US Sale
- Prefilled Syringe Demand by Therapeutic Class
- Encapsulated Parenteral Drug Delivery System Demand by Type & Therapeutic
Class
- Premixed IV Solution Demand by Therapeutic Class
SECTION VII -- INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- Other Drug Delivery System Demand by Type
- Inhalation Drug Delivery System Demand by Type & Therapeutic Class
- Transdermal Drug Delivery System Demand by Therapeutic Class
- Implantable Drug Delivery System Demand by Type & Therapeutic Class
SECTION VIII -- APPLICATIONS
- Drug Delivery System Demand by Therapeutic Class
- Central Nervous System Drug Delivery Demand by Type
- Respiratory Drug Delivery Demand by Type
- Hormone & Related Drug Delivery Demand by Type
- Gastrointestinal Drug Delivery System Demand by Type
- Cardiovascular Drug Delivery System Demand by Type
- Anti-Infective Drug Delivery System Demand by Type
- Nutritional Delivery System Demand by Type
- Biological Delivery System Demand by Type
- Genito-Urinary Drug Delivery System Demand
- Drug Delivery System Demand in Other Therapies
SECTION IX -- INDUSTRY STRUCTURE
- Drug Delivery Revenues by Company, 2007
- Selected Acquisitions & Divestitures
- Selected Cooperative Agreements
LIST OF CHARTS
SECTION III -- DRUG DELIVERY MATERIALS
- Drug Delivery Material Demand by Type, 2007
SECTION IV -- DRUG DELIVERY SYSTEMS OVERVIEW
- Drug Delivery System Demand by Dosage Formulation, 2007
SECTION V -- ORAL DRUG DELIVERY SYSTEMS
- Oral Drug Delivery System Demand by Type, 2007
SECTION VI -- PARENTERAL DRUG DELIVERY SYSTEMS
- Parenteral Drug Delivery System Demand by Type, 2007
SECTION VII -- INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- Inhalation, Transdermal & Implantable Drug Delivery System Demand by Type,
2007
SECTION VIII -- APPLICATIONS
- Drug Delivery System Demand by Therapeutic Class, 2007
SECTION IX -- INDUSTRY STRUCTURE
- US Drug Delivery Product Sales by Company, 2007
|
